Clinical Trial Update: Immunotherapy With Racotumomab in Advanced Lung Cancer [Phase 3]

View source ↗

Summary

This clinical trial update reports on a Phase 3 study of racotumomab immunotherapy in advanced non-small cell lung cancer, sponsored by Recombio SL.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Racotumomab (racotumomab)

Snippet

Sponsor: Recombio SL | Conditions: NSCLC, Lung Cancer, Non-small Cell | Phase 3 | Status: UNKNOWN